Skip to Content

Generic Selzentry Availability

Selzentry is a brand name of maraviroc, approved by the FDA in the following formulation(s):

SELZENTRY (maraviroc - tablet;oral)

  • Manufacturer: VIIV HLTHCARE
    Approval date: August 6, 2007
    Strength(s): 150MG, 300MG [RLD]

Has a generic version of Selzentry been approved?

No. There is currently no therapeutically equivalent version of Selzentry available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Selzentry. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • CCR5 modulators
    Patent 6,586,430
    Issued: July 1, 2003
    Inventor(s): Duncan Robert; Armour & David Anthony; Price & Blanda Luzia Christa; Stammen & Anthony; Wood & Manoussos; Perros & Martin Paul; Edwards
    Assignee(s): Pfizer Inc.
    Compounds of Formula 1 [Region &agr;]-[Region &bgr;]-[Region &ggr;]-[Region &dgr;]  (I) which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.
    Patent expiration dates:
    • December 1, 2019
      ✓ 
      Patent use: METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Tropane derivatives useful in therapy
    Patent 6,667,314
    Issued: December 23, 2003
    Inventor(s): Manoussos; Perros & David Anthony; Price & Blanda Luzia Christa; Stammen & Anthony; Wood
    Assignee(s): Pfizer, Inc.
    The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
    Patent expiration dates:
    • August 6, 2021
      ✓ 
      Patent use: METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Tropane derivatives useful in therapy
    Patent 7,368,460
    Issued: May 6, 2008
    Inventor(s): Perros; Manoussos & Price; David Anthony & Stammen; Blanda Luzia Christa & Wood; Anthony
    Assignee(s): Pfizer, Inc.
    The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
    Patent expiration dates:
    • November 25, 2022
      ✓ 
      Patent use: METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
  • Tropane derivatives useful in therapy
    Patent 7,576,097
    Issued: August 18, 2009
    Inventor(s): Perros; Manoussos & Price; David Anthony & Stammen; Blanda Luzia Christa & Wood; Anthony
    Assignee(s): Pfizer, Inc.
    The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.
    Patent expiration dates:
    • May 25, 2021
      ✓ 
      Drug substance

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide